Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy

References

• Witebsky E, Rose NR, Terplan K. Chronic thyroiditis and autoimmunization. JAMA 1957; 164: 1439–1447
   PubMed Web of Science ®Google Scholar
• Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993; 14: 426–428
   PubMedGoogle Scholar
• Bottazzo GF, Todd I, Mirakian R, et al. Organ-specific autoimmunity. A 1986 overview. Immunol Rev 1986; 94: 137–169
   PubMed Web of Science ®Google Scholar
• MacLellan RW, Lusis AJ. Dilated cardiomyopathy: Learning to live with yourself. Nat Med 2003; 9: 1455–1456
   PubMed Web of Science ®Google Scholar
• Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003; 9: 1477–1483
   PubMed Web of Science ®Google Scholar
• Eriksson U, Ricci R, Hunziker L, et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003; 9: 1484–1490
   PubMed Web of Science ®Google Scholar
• Richardson P, McKenna WJ, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841–842
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Changes in mortality from heart failure, United States. JAMA 1998; 280: 874–875
   PubMed Web of Science ®Google Scholar
• Morita H, Seidman J, Seidman CE. Genetic causes of human heart failure. J Clin Invest 2005; 115: 518–526
   PubMed Web of Science ®Google Scholar
• Aretz HT, Billingham ME, Edwards WE, et al. Myocarditis: A histopathologic definition and classification. Am J Cardiovasc Pathol 1985; 1: 1–10
   Google Scholar
• Caforio ALP, McKenna WJ. Recognition and optimum treatment of myocarditis. Drugs 1996; 52: 515–525
   PubMed Web of Science ®Google Scholar
• Caforio ALP. Role of autoimmunity in dilated cardiomyopathy. Br Heart J 1994; 72: S30–S34
   Google Scholar
• Baig MK, Goldman JH, Caforio ALP, et al. Familial dilated cardiomyopathy: Cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol 1998; 31: 195–201
   PubMed Web of Science ®Google Scholar
• Anderson JL, Carlquist JF, Lutz JR, et al. HLA A, B, and DR typing in idiopathic dilated cardiomyopathy: A search for immune response factors. Am J Cardiol 1984; 53: 1326–1330
   PubMed Web of Science ®Google Scholar
• Caforio ALP, Stewart JT, Bonifacio E, et al. Inappropriate major histocompatibility complex expression on cardiac tissue in dilated cardiomyopathy. Relevance for autoimmunity?. J Autoimmun 1990; 3: 187–200
   PubMed Web of Science ®Google Scholar
• Mahon NG, Madden B, Caforio ALP, et al. Immunohistochemical evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 39: 455–462
   PubMed Web of Science ®Google Scholar
• Caforio ALP, Mahon NJ, Tona F, et al. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: Pathogenetic and clinical significance. Eur J Heart Fail 2002; 4: 411–417
   PubMed Web of Science ®Google Scholar
• Caforio ALP, Keeling PJ, Zachara E, et al. Evidence from family studies for autoimmunity in dilated cardiomyopathy. Lancet 1994; 344: 773–777
   PubMed Web of Science ®Google Scholar
• Caforio ALP, Mahon NG, Baig KM, et al. Prospective familial assessment in dilated cardiomyopathy. Cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 2007; 115: 76–83
   PubMed Web of Science ®Google Scholar
• Fletcher GF, Wenger NK. Autoimmune studies in patients with primary myocardial disease. Circulation 1968; 37: 1032–1035
   PubMed Web of Science ®Google Scholar
• Camp FT, Hess EV, Conway G, et al. Immunologic findings in idiopathic cardiomyopathy. Am Heart J 1969; 77: 610–615
   PubMed Web of Science ®Google Scholar
• Kirsner AB, Hess EV, Fowler NO. Immunologic findings in idiopathic cardiomyopathy: A prospective serial study. Am Heart J 1973; 86: 625–630
   PubMed Web of Science ®Google Scholar
• Maisch B, Deeg P, Liebau G, et al. Diagnostic relevance of humoral and cytotoxic immune reactions in primary and secondary dilated cardiomyopathy. Am J Cardiol 1983; 52: 1071–1078
   Web of Science ®Google Scholar
• Maisch B, Deeg P, Liebau G, et al. Diagnostic relevance of humoral and cell-mediated immune reactions in patients with viral myocarditis. Clin Exp Immunol 1983; 48: 533–545
   Web of Science ®Google Scholar
• Neumann DA, Burek CL, Baughman KL, et al. Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol 1990; 16: 839–846
   PubMedGoogle Scholar
• Caforio ALP, Bonifacio E, Stewart JT, et al. Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol 1990; 15: 1527–1534
   PubMed Web of Science ®Google Scholar
• Caforio ALP, Wagner R, Gill JS, et al. Organ-specific cardiac antibodies: Serological markers for systemic hypertension in autoimmune polyendocrinopathy. Lancet 1991; 337: 1111–1115
   PubMed Web of Science ®Google Scholar
• Caforio ALP, Goldman JH, Haven AJ, et al. Circulating cardiac autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. Eur Heart J 1997; 18: 270–275
   PubMed Web of Science ®Google Scholar
• Betterle C, Spadaccino AC, Pedini B. Autoanticorpi nelle malattie autoimmuni del muscolo scheletrico, della giunzione neuro-muscolare e del cuore. Gli autoanticorpi. Manuale-Atlante a colori di diagnostica, C Betterle. Piccin, Padova 1997; 313–337
   Google Scholar
• Nicholson GC, Dawkins RL, McDonald BL, et al. A classification of anti-heart antibodies: Differentiation between heart-specific and heterophile antibodies. Clin Immunol Immunopathol 1977; 7: 349–363
   PubMedGoogle Scholar
• Caforio ALP, Grazzini M, Mann JM, et al. Identification of α and β cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992; 85: 1734–1742
   PubMed Web of Science ®Google Scholar
• Caforio ALP, Goldman JH, Baig KM, et al. Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression. Heart 1997; 77: 62–67
   PubMed Web of Science ®Google Scholar
• Lauer B, Schannwell M, Kuhl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000; 35: 11–18
   PubMed Web of Science ®Google Scholar
• Latif N, Baker CS, Dunn MJ, et al. Frequency and specificity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and western blotting. J Am Coll Cardiol 1993; 22: 1378–1384
   PubMed Web of Science ®Google Scholar
• Goldman JH, Keeling PJ, Warraich RS, et al. Autoimmunity to α-myosin in a subset of patients with idiopathic dilated cardiomyopathy. Br Heart J 1995; 74: 598–603
   PubMedGoogle Scholar
• Michels VV, Moll PP, Rodeheffer RJ, et al. Circulating heart autoantibodies in familial as compared with nonfamilial idiopathic dilated cardiomyopathy. Mayo Clin Proc 1994; 69: 24–27
   PubMed Web of Science ®Google Scholar
• Konstandoulakis MM, Kroumbouzou H, Tsiamis E, Trikas A, Toutouzas P. Clinical significance of antibodies against tropomyosin, actin and myosin in patients with dilated cardiomyopathy. J Clin Lab Immunol 1993; 40: 61–67
   PubMedGoogle Scholar
• Warraich RS, Dunn MJ, Yacoub MH. Subclass specificity of autoantibodies against myosin in patients with idiopathic dilated cardiomyopathy: Proinflammatory antibodies in dilated cardiomyopathy patients. Biochem Biophys Res Commun 1999; 259: 255–261
   PubMed Web of Science ®Google Scholar
• Portig I, Pankuweit S, Maisch B. Antibodies against stress proteins in sera of patients with dilated cardomyopathy. J Mol Cell Cardiol 1997; 29: 2245–2251
   PubMed Web of Science ®Google Scholar
• Latif N, Smith J, Dunn MJ, et al. Complement-mediated cytotoxic activity of anti-heart antibodies present in the sera of patients with dilated cardiomyopathy. Autoimmunity 1994; 19: 99–104
   PubMed Web of Science ®Google Scholar
• Baba A, Yoshikawa T, Ogawa S. Autoantibodies against sarcolemmal Na–K-ATPase: Possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 40: 1153–1159
   PubMed Web of Science ®Google Scholar
• Wolff PG, Kuhl U, Schultheiss HP. Laminin distribution and autoantibodies to laminin in dilated cardiomyopathy and myocarditis. Am Heart J 1989; 117: 1303–1309
   PubMed Web of Science ®Google Scholar
• Klein R, Maisch B, Kochsiek K, et al. Demonstration of organ specific antibodies against heart mitochondria (anti-M7) in sera from patients with some forms of heart diseases. Clin Exp Immunol 1984; 58: 283–292
   PubMed Web of Science ®Google Scholar
• Otto A, Stahle I, Klein R, et al. Anti-mitochondrial antibodies in patients with dilated cardiomyopathy (anti-M7) are directed against flavoenzymes with covalently bound FAD. Clin Exp Immunol 1998; 111: 541–547
   PubMed Web of Science ®Google Scholar
• Schultheiss HP, Bolte HD. Immunological analysis of auto-antibodies against the adenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol 1985; 17: 603–617
   PubMed Web of Science ®Google Scholar
• Schultheiss HP, Kuhl U, Schwimmbeck P, . Biomolecular changes in dilated cardiomyopathy. Advances in cardiomyopathies, G Baroldi, F Camerini, JF Goodwin, et al. Springer Verlag, Berlin 1990; 221–234
   Google Scholar
• Ansari AA, Neckelmann N, Villinger F, et al. Epitope mapping of the branched chain α-ketoacid dehydrogenase dihydrolipoyl transacylase (BCKD-E2) protein that reacts with sera from patients with idiopathic dilated cardiomyopathy. J Immunol 1994; 153: 4754–4765
   PubMed Web of Science ®Google Scholar
• Pohlner K, Portig I, Pankuweit S, et al. Identification of mitochondrial antigens recognized by antibodies in sera of patients with idiopathic dilated cardiomyopathy by two-dimensional gel electrophoresis and protein sequencing. Am J Cardiol 1997; 80: 1040–1045
   PubMed Web of Science ®Google Scholar
• Schultheiss HP, Ulrich G, Janda I, et al. Antibody mediated enhancement of calcium permeability in cardiac myocytes. J Exp Med 1988; 168: 2105–2119
   PubMed Web of Science ®Google Scholar
• Wallukat G, Morwinski M, Kowal K, et al. Antibodies against the β-adrenergic receptor in human myocarditis and dilated cardiomyopathy: β-Adrenergic agonism without desensitization. Eur Heart J 1991; 12(Suppl D)178–181
   PubMed Web of Science ®Google Scholar
• Limas CJ, Goldenberg IF, Limas C. Autoantibodies against β-adrenoceptors in idiopathic dilated cardiomyopathy. Circ Res 1989; 64: 97–103
   PubMed Web of Science ®Google Scholar
• Limas CJ, Limas C. β-Receptor antibodies and genetics in dilated cardiomyopathy. Eur Heart J 1991; 12(Suppl D)175–177
   PubMedGoogle Scholar
• Magnusson Y, Marullo S, Hoyer S, et al. Mapping of a functional autoimmune epitope on the β-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1990; 86: 1658–1663
   PubMed Web of Science ®Google Scholar
• Magnusson Y, Wallukat G, Waagstein F, et al. Autoimmunity in idiopathic dilated cardiomyopathy: Characterization of antibodies against the β1-adrenoceptor with positive chronotropic effect. Circulation 1994; 89: 2760–2767
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Siegmund C, et al. Autoantibodies activating human β1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999; 99: 649–654
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Krapf T, et al. Modulation of β1-adrenoceptor activity by domain-specific antibodies and heart-failure associated autoantibodies. J Am Coll Cardiol 2000; 36: 1280–1287
   PubMed Web of Science ®Google Scholar
• Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993; 91: 1964–1968
   PubMed Web of Science ®Google Scholar
• Marriott JB, Goldman JH, Keeling PJ, Baig MK, Dalgleish AG, McKenna WJ. Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart 1996; 75: 287–290
   PubMed Web of Science ®Google Scholar
• Rose NR. Viral damage or “molecular mimicry”–placing the blame in myocarditis. Nat Med 2000; 6: 631–632
   PubMed Web of Science ®Google Scholar
• Kuan AP, Zuckier L, Liao L, et al. Immunoglobulin isotype determines pathogenicity in antibody-mediated myocarditis in naïve mice. Circ Res 2000; 86: 281–285
   PubMed Web of Science ®Google Scholar
• Neu N, Rose NR, Beisel KW, et al. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 1987; 139: 3630–3636
   PubMed Web of Science ®Google Scholar
• Smith SC, Allen PM. Myosin-induced myocarditis is a T cell-mediated disease. J Immunol 1991; 147: 2141–2147
   PubMed Web of Science ®Google Scholar
• Zweiman B, Arnason BGW. Immunologic aspects of neurological and neuromuscolar diseases. JAMA 1987; 258: 2970–2973
   PubMedGoogle Scholar
• Bonifacio E, Bingley PJ, Shattock M, et al. Quantitation of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 1990; 335: 147–149
   PubMed Web of Science ®Google Scholar
• Mahon NG, Murphy RT, MacRae C, Caforio ALP, Elliott PM, McKenna WJ. Echocardiographic evaluation in asymptomatic relatives of dilated cardiomyopathy patients reveals preclinical disease. Ann Intern Med 2005; 143: 108–115
   PubMed Web of Science ®Google Scholar
• Mrena S, Savola K, Kulmala P, et al. Genetic modification of risk assessment based on staging of preclinical type 1 diabetes in siblings of affected children. J Clin Endocrinol Metab 2003; 88: 2682–2689
   PubMed Web of Science ®Google Scholar
• Warraich RS, Griffiths E, Falconar A, et al. Human cardiac myosin autoantibodies impair myocyte contractility: A cause-and-effect relationship. FASEB J 2006; 20: 651–660
   PubMed Web of Science ®Google Scholar
• Horwitz MS, La Cava A, Fine C, et al. Pancreatic expression of interferon-γ protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat Med 2000; 6: 693–707
   PubMed Web of Science ®Google Scholar
• Galvin JE, Hemric ME, Ward K, et al. Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. J Clin Invest 2000; 106: 217–224
   PubMed Web of Science ®Google Scholar
• Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 2006; 177: 8234–8240
   PubMed Web of Science ®Google Scholar
• Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319–322
   PubMed Web of Science ®Google Scholar
• Mobini R, Staudt A, Felix SB, et al. Hemodynamic improvement and removal of autoantibodies against the β1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 2003; 20: 345–350
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. Trends Mol Med 2005; 11: 322–326
   PubMed Web of Science ®Google Scholar
• Urayama O, Shutt H, Sweadner J. Identification of three isozyme proteins of the catalytic subunit of the Na, K-ATPase in rat brain. J Biol Chem 1989; 264: 8271–8280
   PubMed Web of Science ®Google Scholar
• Muller-Ehmsen J, Juvvadi P, Thompson CB, et al. Ouabain and substrate affinities of human Na–K-ATPase α-1β-1, α-2β-1, α-3β-1 when expressed separately in yeast cells. Am J Physiol Cell Physiol 2001; 281: C1355–C1364
   Web of Science ®Google Scholar
• Schwinger RH, Wang J, Frank K, et al. Reduced sodium pump α1-, α3-, β1-isoform protein levels and Na,K-ATPase activity but unchanged Na/Ca exchanger protein levels in human heart failure. Circulation 1999; 99: 2105–2112
   PubMed Web of Science ®Google Scholar
• Matsui S, Fu ML, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 1997; 29: 641–655
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Hein L, et al. Direct evidence for a β1-adrenergic receptor directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004; 113: 1419–1429
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Lohse MJ, et al. β1-Adrenergic receptor function, autoimmunity and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med 2006; 16: 20–24
   PubMed Web of Science ®Google Scholar
• Eglen RM, Reddy H, Watson N, et al. Muscarinic acetylcholine receptor subtypes in smooth muscle. Trend Pharmacol Sci 1994; 15: 114–119
   PubMed Web of Science ®Google Scholar
• Elalouf JM, Buhler JM, Tessiot C, et al. Predominant expression of beta 1-adrenergic receptor in the thick ascending limb of rat kidney: Absolute mRNA quantitation by reverse trascription and polymerase chain reaction. J Clin Invest 1993; 91: 264–272
   PubMed Web of Science ®Google Scholar
• Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995; 333: 269–275
   PubMed Web of Science ®Google Scholar
• Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Two-year follow-up results. Circulation 2001; 104: 39–45
   PubMed Web of Science ®Google Scholar
• Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: Virological and immunologic profile of responders versus nonresponders. Circulation 2003; 107: 857–863
   PubMed Web of Science ®Google Scholar
• Muller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101: 385–391
   PubMed Web of Science ®Google Scholar
• Schimke I, Muller J, Priem F, et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 2001; 38: 178–183
   PubMed Web of Science ®Google Scholar
• Felix SB, Staudt A, Landsberger M, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002; 39: 646–652
   PubMed Web of Science ®Google Scholar
• Staudt A, Bohm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002; 106: 2448–2453
   PubMed Web of Science ®Google Scholar
• Mann DL. Autoimmunity, immunoglobulin adsorption and dilated cardiomyopathy: Has the time come for randomized clinical trials?. J Am Coll Cardiol 2001; 38: 184–186
   PubMed Web of Science ®Google Scholar
• Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220–225
   PubMed Web of Science ®Google Scholar